Evidence map›Paper›PMID 33327259›Full record

ArticleMedicine2020

Computational study on natural compounds inhibitor of c-Myc.

Junan Ren, Yuhao Huangfu, Junliang Ge, Bo Wu, Weihang Li, Xinhui Wang, Liyan Zhao

Open access · goldAbstract read
In one paragraph

Article in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Junan RenClinical College, Jilin University, Changchun.
Yuhao HuangfuDepartment of Medicine, Boston University.
Junliang GeClinical College, Jilin University, Changchun.
Bo WuClinical College, Jilin University, Changchun.
Weihang LiDepartment of Orthopaedics, Xijing Hospital, The Fourth Military Medical University, Xian, China.
Xinhui WangClinical College, Jilin University, Changchun.
Liyan ZhaoDepartment of Clinical Laboratory, The Second Hospital of Jilin University.
Jilin University · CNBoston University · USSecond Affiliated Hospital of Jilin University · CNXijing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To screen and identify ideal leading compounds from a drug library (ZINC15 database) with potential inhibition effect against c-Myc to contribute to medication design and development.A series of computer-aided virtual screening techniques were performed to identify potential inhibitors of c-Myc. LibDock from the software Discovery Studio was used to do a structure-based screening after ADME (absorption, distribution, metabolism, excretion) and toxicity prediction. Molecular docking was utilized to show the binding affinity and potential mechanism between ligands and c-Myc. Stability of the ligand-receptor complex was analyzed by molecular dynamic simulation at the end of the research.Compounds with more interactive energy which are confirmed to be the potential inhibitors for c-Myc were identified from the ZINC15 databases. Additionally, those compounds are also anticipated with fewer ames mutagenicity, rodent carcinogenicity, nondevelopmental toxic potential, and tolerant with cytochrome p450 2D6(CYP2D6). Dynamic simulation analysis also revealed that the very compounds had more favorable potential energy compared with 10058-F4(ZINC12406714). Furthermore, we prove that those compounds are stable and can exist in natural conditions.This study demonstrates that the compounds are potential therapeutic inhibitors for c-Myc. These compounds are safe and stable for drug candidates and may play a critical role in c-Myc inhibitor development.

Indexed as

Drug Evaluation, PreclinicalMolecular Dynamics SimulationAntineoplastic AgentsBinding SitesHumansMolecular Docking SimulationProtein ConformationProto-Oncogene Proteins c-mycSmall Molecule LibrariesStructure-Activity RelationshipAntineoplastic AgentsMYC protein, humanProto-Oncogene Proteins c-mycSmall Molecule Libraries

Identifiers

PMID33327259
PMCPMC7738058
OpenAlexW3111908199

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.